Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Update

Lonza Group Ag (OTCMKTS:LZAGYGet Free Report) saw a significant growth in short interest in June. As of June 30th, there was short interest totaling 31,620 shares, a growth of 281.6% from the June 15th total of 8,286 shares. Based on an average daily volume of 93,974 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the shares of the stock are short sold.

Lonza Group Stock Performance

LZAGY traded down $0.64 during mid-day trading on Monday, hitting $71.99. The stock had a trading volume of 24,045 shares, compared to its average volume of 82,364. The stock’s fifty day simple moving average is $63.99 and its 200-day simple moving average is $65.47. Lonza Group has a 1-year low of $58.53 and a 1-year high of $73.85. The company has a current ratio of 2.24, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Lonza Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.

View Our Latest Stock Analysis on Lonza Group

Lonza Group Company Profile

(Get Free Report)

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

Featured Stories

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.